NR vs. NMN: The NAD+ Precursor Label Question, the 250-to-500 mg Studied-Dose Bracket, and Why the 100 mg Retail Default Is a Pixie-Dust Position on the Most Expensive Ingredient on the Shelf

Walk into any premium wellness retailer and look at the anti-aging supplement wall. Somewhere on that wall there will be a section — sometimes an entire endcap — devoted to NAD+ precursors. Two ingredients dominate the shelf: nicotinamide riboside (NR), most commonly appearing as the trademarked Niagen ingredient produced by ChromaDex, and nicotinamide mononucleotide (NMN), sold under a dozen different manufacturer names with widely variable purity specifications. The bottles sit next to each other, they are priced similarly, and the marketing on both talks about cellular energy, mitochondrial function, DNA repair, and the sirtuin pathway with roughly interchangeable language.

Pick up the bottles and read the Supplement Facts. In the majority of retail NAD+ precursor products in the U.S. market, the serving size delivers 100 to 250 mg of NR or NMN per serving. A subset of premium brands go to 300 mg. A very small number of practitioner-channel products go to 500 mg or 1,000 mg per serving. The overwhelming majority of the shelf sits at the 100 to 250 mg dose that maps to the low end of the studied dose range and produces a proportionally reduced plasma-NAD+ response compared to the trials that produced the marketing claims.

The reason the retail industry has landed at this dose is straightforward: NR and NMN are among the most expensive ingredients per gram in the entire supplement category. Niagen NR runs manufacturers roughly $8 to $15 per gram of finished ingredient depending on volume and contract; pharmaceutical-grade NMN runs $10 to $30 per gram depending on the purity spec. A 30-serving bottle of NR at 300 mg per serving contains 9 grams of Niagen at a raw-material cost of $72 to $135 before packaging, labeling, distribution margin, and retail markup. The same product at 100 mg per serving contains 3 grams of Niagen at a raw-material cost of $24 to $45. The gross-margin difference is the reason the shelf has landed where it has, and it is why a consumer paying $40 to $80 for a bottle of NR or NMN is frequently paying a premium price for a fraction of the studied dose.

What NR and NMN Actually Are and How They Feed the NAD+ Pool

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell in the body, functioning as the electron carrier in mitochondrial energy metabolism, as the substrate for the sirtuin family of enzymes that regulate metabolic and epigenetic responses, and as the substrate for the PARP enzymes that repair DNA damage. NAD+ levels decline meaningfully with age — human tissue biopsy studies have shown 30 to 50 percent reductions in tissue NAD+ from age 30 to age 70 in muscle, brain, skin, and liver — and the age-related decline has become the anchor point for the anti-aging supplement conversation around NAD+ precursors.

NAD+ itself cannot be effectively supplemented orally — it is a large charged molecule that does not survive digestion and does not cross membranes into cells intact. The intracellular NAD+ pool is maintained through three synthesis pathways: de novo synthesis from tryptophan (minor contributor in most tissues), the Preiss-Handler pathway from nicotinic acid (niacin), and the salvage pathway from various nicotinamide-containing precursors. NR and NMN both feed the salvage pathway, and this is where the pharmacology of the two precursors starts to diverge in ways the marketing collapses.

Nicotinamide riboside (NR). A nucleoside consisting of nicotinamide attached to a ribose sugar. Absorbed intact through nucleoside transporters, distributed to tissues through the bloodstream, and phosphorylated intracellularly by the NRK1 and NRK2 kinases to form NMN, which is then converted to NAD+ by NMNAT enzymes. The two-step intracellular conversion is well-characterized, the NRK kinases are expressed in most tissues, and the pathway from oral NR to intracellular NAD+ has been demonstrated in multiple human pharmacokinetic and NAD+-elevation studies.

Nicotinamide mononucleotide (NMN). A nucleotide consisting of nicotinamide, ribose, and a phosphate group. The oral absorption pathway for NMN is where the pharmacology gets contested. Original mechanistic work in mice proposed a direct NMN transporter (Slc12a8) in the small intestine that would take up intact NMN, but the direct-transporter finding has not consistently replicated in human tissue studies. The dominant view in the current human pharmacokinetic literature is that oral NMN is largely dephosphorylated to NR at the intestinal brush border, absorbed as NR through the nucleoside transporters, and then converted back to NMN and NAD+ intracellularly through the same pathway NR uses. If this is the correct interpretation, oral NMN and oral NR are pharmacologically nearly equivalent — with NMN carrying a somewhat higher molecular weight per equivalent dose of the nicotinamide moiety and higher per-gram cost.

The direct-NMN-transporter question is still being investigated and the literature has not fully settled it. What has settled is that both NR and NMN, dosed orally in human trials at the ranges used in the reference studies, raise plasma NAD+ metabolite concentrations in a reproducible and roughly comparable way. The "NMN is better than NR because it's one step closer to NAD+" marketing framing is a mechanistic story that does not survive the current human pharmacokinetic data if oral NMN is largely dephosphorylated to NR at absorption.

The Studied Dose Bracket — 250 to 1,000 mg per Day

The human clinical trial evidence for both NR and NMN spans a dose range from roughly 100 mg per day at the low end (mostly early tolerability and pharmacokinetic studies) to 2,000 mg per day at the high end (a smaller number of higher-dose PK and clinical-effect studies). The reproducible plasma-NAD+-elevation dose bracket sits at approximately 250 to 1,000 mg per day, taken as a single daily dose or split across two doses, for a minimum of 4 to 8 weeks before endpoint measurement. Four evidence buckets:

Plasma NAD+ metabolite elevation. The most-replicated endpoint across NR and NMN trials. NR dosed at 250 to 1,000 mg per day for 4 to 12 weeks produces plasma-NAD+-metabolite increases of 40 to 90 percent in the Trammell et al. (2016), Martens et al. (2018), Airhart et al. (2017), and Elhassan et al. (2019) trials among others. NMN dosed at 250 to 1,000 mg per day for 4 to 12 weeks produces comparable plasma-NAD+-metabolite increases in the Yoshino et al. (2021), Yamane et al. (2023), and Kim et al. (2022) trials. Below 250 mg per day the plasma-NAD+ elevation signal is smaller and less consistent; above 1,000 mg per day the incremental gain per additional milligram plateaus.

Blood pressure and vascular function. The Martens et al. (2018) trial in older adults (55 to 79 years) at 500 mg NR twice daily (1,000 mg total) for 6 weeks showed a modest reduction in systolic blood pressure (roughly 8 mmHg) in participants with elevated baseline blood pressure. Other trials at lower NR doses have not consistently reproduced the vascular signal, and the effect size is modest.

Muscle function and mitochondrial markers. Multiple trials of NR at 500 to 1,000 mg per day in older adults have shown improvements in some mitochondrial-function markers, some measures of walking economy, and inconsistent effects on functional performance endpoints (grip strength, chair-rise time, gait speed). The signal is real but modest and highly dependent on the population and the endpoint. NMN trials at comparable doses have shown similar patterns.

Metabolic and glycemic markers. The Yoshino et al. (2021) trial of 250 mg NMN per day for 10 weeks in prediabetic postmenopausal women showed a modest improvement in muscle insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp. Other NR and NMN trials have shown mixed effects on fasting glucose, insulin sensitivity, and lipid markers, with the strongest signals in populations with baseline metabolic dysfunction.

Across all four evidence buckets, the dose range where the effects were observed is 250 to 1,000 mg per day. The 100 mg per serving retail default sits below the low end of the studied range and produces a proportionally reduced plasma-NAD+ response, and the clinical effects that depend on the NAD+ elevation follow the dose-response.

Why the Retail Standard Is 100 mg Anyway

Three drivers landed the retail industry at the 100 to 250 mg per serving default despite the 300 to 1,000 mg trial doses.

Raw-material cost. As above. NR and NMN are among the most expensive supplement ingredients per gram, and the difference between a 300 mg serving and a 100 mg serving is a threefold difference in ingredient cost per bottle. A retailer selling a 100 mg NR product at $50 for 30 servings is running roughly a $2.40 to $4.50 raw-material cost per bottle and a healthy gross margin. The same retailer selling a 300 mg NR product at the same $50 shelf price is running $7.20 to $13.50 raw-material cost and a compressed margin, or has to charge $75 to $90 to preserve the margin. The market has landed at 100 to 250 mg as the price-friendly serving.

"NAD+ support" positioning as a marketing category rather than a dose-driven category. The bottle earns its way onto the anti-aging shelf on the ingredient name and the mechanism story, not on the dose. Consumers reading the marketing about mitochondrial function and cellular energy are not typically running the arithmetic against the studied dose range. The 100 mg serving qualifies the product as an "NR product" or an "NMN product" without delivering the studied dose, and the shelf-adjacency does the marketing work.

Multi-ingredient stacking that further dilutes the NR/NMN dose. A subset of NAD+ precursor products combine NR or NMN with resveratrol, pterostilbene, quercetin, coenzyme Q10, and various other longevity-adjacent ingredients in one capsule or tablet. In these formulations the NR/NMN dose typically drops to 50 to 150 mg per serving because the ingredient cost is spread across multiple line items on the label. The stack-marketing story ("comprehensive longevity support") displaces the dose conversation on any single ingredient, and the consumer buying the stack for the NR content is buying a fraction of what a standalone NR product would deliver at the same total price.

The Regulatory Situation That Reshuffled the NMN Market

In late 2022 the FDA notified the supplement industry that NMN did not meet the definition of a "dietary ingredient" under the Dietary Supplement Health and Education Act (DSHEA) because a pharmaceutical company had earlier filed an Investigational New Drug (IND) application for NMN, triggering the "drug preclusion" provision that prohibits substances undergoing drug investigation from being marketed as dietary supplements. Following that notification, several major online retailers (Amazon most notably) removed NMN products from their catalogs, and a subset of manufacturers pivoted their NAD+ precursor product lines to NR (which does not carry the same drug-preclusion status) or restructured their NMN products to comply with the guidance.

As of 2026, the NMN regulatory situation remains partially unresolved. NMN is still sold by many manufacturers through direct-to-consumer channels and through some retailers, but the market is smaller than it was in 2020 to 2022 and the product-availability picture is inconsistent across retailers. NR through the trademarked Niagen ingredient produced by ChromaDex has a New Dietary Ingredient (NDI) notification and Generally Recognized as Safe (GRAS) status that has kept it commercially available across all major retailers.

The practical implication for a consumer: if the choice on the shelf is between an NR product with clear regulatory status and NDI/GRAS documentation and an NMN product from a manufacturer with unclear regulatory position, the NR product carries less regulatory uncertainty. This is not a claim that NR is pharmacologically superior — the human data on plasma-NAD+ elevation is roughly comparable between the two at equivalent doses — but the supply-chain and regulatory-continuity picture favors NR at the current moment.

The Source and Purity Question That Is Bigger for NMN Than for NR

Ingredient quality and purity vary widely across the NAD+ precursor supplement category, and the variation is larger for NMN than for NR.

NR (Niagen from ChromaDex). The overwhelming majority of NR supplements on the U.S. market use Niagen, which is a trademarked ingredient produced through a specific patented synthesis process with defined purity specifications. Third-party analytical testing of Niagen products has generally shown label-declared NR content matching actual assay values within tight tolerances. The manufacturing consistency is one of the reasons NR has held onto shelf space through the regulatory reshuffling.

NMN (multiple manufacturers, variable specifications). NMN is produced by a wider set of manufacturers, primarily in China, with widely variable purity specifications and analytical testing standards. Third-party analytical testing of NMN products from multiple independent labs across 2022 to 2024 has shown label-declared NMN content varying from 60 percent to 105 percent of the label claim depending on the manufacturer, with a subset of products delivering meaningfully less NMN than the label indicated. The consumer paying for a 300 mg NMN serving from a low-quality manufacturer may be receiving 200 mg or less of actual NMN plus various process impurities.

The label features that indicate a manufacturer taking purity seriously: specific declaration of the NMN purity percentage (typically 98 percent or higher for pharmaceutical-grade), Certificate of Analysis (COA) availability with third-party assay verification, and disclosure of the manufacturing location and quality-control standards. NMN products without any of these declarations should be treated with skepticism regardless of the label dose.

The Empty-Stomach vs. Fat-Meal Question and the Timing Question

NR and NMN are water-soluble compounds and their oral absorption does not depend on fat coingestion the way lipid-soluble supplements do. Timing of the dose has been less studied than dose amount but the general pattern in the human PK studies is that a morning dose taken on an empty stomach or with a light breakfast produces reproducible plasma-NAD+-metabolite elevation across the day.

Some manufacturers recommend split dosing (half in the morning, half in the afternoon or evening) based on the hypothesis that the NAD+ pool turns over rapidly and split dosing maintains a more sustained elevation. The PK data supports this hypothesis loosely — plasma NR/NMN peaks within 1 to 2 hours of dosing and returns toward baseline by 6 to 8 hours in most studies — but the clinical-effect data does not clearly distinguish single-dose from split-dose regimens at equivalent total daily dose. Take the full daily dose as a single morning dose or split it; the data does not strongly prefer one pattern.

Late-evening dosing is worth considering separately: because NR and NMN participate in the NAD+/NADH-driven circadian and sirtuin signaling that regulates the sleep-wake cycle, a late-evening NAD+ precursor dose may have a subjective activating effect in some individuals and may interfere with sleep onset. If you notice a sleep-disruption pattern after starting NR or NMN, shift the dose to morning-only.

The 20-Second Supplement Facts Read

Pick up the bottle. Answer four questions.

One: what is the per-serving dose against the 250 to 1,000 mg studied bracket? If the answer is 100 mg or 125 mg, the product sits below the low end of the studied dose range and delivers a proportionally reduced plasma-NAD+-elevation effect. If the answer is 250 mg or 300 mg, the product sits at the low end of the studied range and delivers a threshold effect. If the answer is 500 mg or higher, the product sits in the middle of the studied range and delivers the fuller effect the marketing claims rest on. Multiply by servings per day if the label directs multiple daily servings; a 150 mg serving at "two capsules twice daily" delivers 600 mg per day and clears the studied threshold.

Two: for NR, is the source Niagen (or another named trademarked NR ingredient with NDI/GRAS documentation)? For NMN, does the label disclose the purity percentage, the manufacturing location, and the availability of a third-party Certificate of Analysis? A generic "nicotinamide riboside 250 mg" or "nicotinamide mononucleotide 300 mg" label without the source or purity disclosure is a product where the manufacturing quality is not verifiable, and the consumer should assume the label dose may not fully reflect the actual product content.

Three: is the product a standalone NR/NMN product or a multi-ingredient longevity stack? A standalone product at the studied dose is the transparent position. A multi-ingredient stack with NR or NMN as one of six or eight ingredients is a marketing-ingredient position where the NR/NMN dose has been diluted to fit the price point, and the consumer wanting the NR/NMN benefit at the studied dose is buying the wrong product.

Four: is the price per gram of NR/NMN consistent with the raw-material cost floor? Divide the bottle price by (per-serving milligrams times servings per bottle divided by 1,000) to get a rough price per gram of active ingredient. A price meaningfully below $10 per gram of NR or $15 per gram of NMN is a signal that either the raw material is not what the label says it is, or the retailer is running below-market pricing on a product that will not sustain that price point. A price in the $15 to $50 per gram range is consistent with a reasonably-margined product from a quality manufacturer.

The NAD+ precursor supplement category is one where the studied dose, the source specification, and the price per gram of active ingredient are the three things the label can answer for you. Answer them before the "which precursor is better" marketing debate distracts from what the bottle actually delivers.